A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non‑small‑cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

J. Casal-Rubio,José L. Fírvida-Pérez,Martin Lázaro Quintela,F. J. Barón Duarte,G. Alonso-Jaudenes,Lucía Santomé,Francisco J. Afonso Afonso,Margarita Amenedo,G. Huidobro,B. Campos Balea,M. D. López-Vázquez,S. Vázquez

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non‑small‑cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

2014

J. Casal-Rubio
José L. Fírvida-Pérez
Martin Lázaro Quintela
F. J. Barón Duarte
G. Alonso-Jaudenes
Lucía Santomé
Francisco J. Afonso Afonso
Margarita Amenedo
G. Huidobro
B. Campos Balea
M. D. López-Vázquez
S. Vázquez

Purpose This single arm, phase II study aims to evaluate the role of epidermal growth factor receptor–tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent chemoradiotherapy (cCRT) in unresectable locally advanced non-small-cell lung cancer (NSCLC).

Keywords:

Epidermal growth factor
Chemoradiotherapy
Erlotinib
Phases of clinical research
Stage III Non-Small Cell Lung Cancer
Oncology
Maintenance therapy
Medicine
Lung cancer
Internal medicine
locally advanced
concurrent chemoradiotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations